

## Special Issue

# Vaccination Strategies for COVID-19 II

### Message from the Guest Editor

This Special Issue is a continuation of our previous Special Issue, entitled "Vaccination Strategies for COVID-19" ([https://www.mdpi.com/journal/vaccines/special\\_issues/COVID-19\\_vaccine](https://www.mdpi.com/journal/vaccines/special_issues/COVID-19_vaccine)). We are at the precipice of unprecedented developments in the arena of vaccine development and application. In the wake of COVID-19, government, academia, medicine, science, and engineering have coordinated, matured, and promoted worldwide vaccination strategies as part of the healthcare armamentarium towards curtailing and hopefully eradicating this global pandemic. These include both "tried and true" as well as novel modalities to stimulate the immune system to provide appropriate and hopefully long-lasting protection against the COVID-19 wild-type virus as well as potential variants. In this Special Issue, we entreat those invested in the unique field of vaccine development, application, and the greater healthcare industry to share their understanding with their clinical, scientific, academic, medical, and healthcare colleagues. This will provide a platform to amalgamate efforts and understanding as well as synergize efforts for current and future vaccine initiatives.

### Guest Editor

Prof. Dr. Martin H. Bluth

1. Blood Transfusion and Donor Services, Maimonides Medical Center, Brooklyn, NY, USA
2. Department of Pathology, Wayne State University School of Medicine, Detroit, MI, USA

### Deadline for manuscript submissions

closed (20 January 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/156965](https://mdpi.com/si/156965)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).